Literature DB >> 7417789

Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats.

J S Fink, G P Smith.   

Abstract

Rats explore a novel open field or novel object less after denervation of mesolimbicocortical dopaminergic terminal fields produced by bilateral 6-hydroxydopamine (6-OHDA) microinjections into the anterolateral hypothalamus after pretreatment with desmethylimipramine (DMI). These behavioral deficits were correlated with complete or nearly complete loss of fluorescent dopaminergic (DA) terminals in the nucleus accumbens, olfactory tubercle, dorsal bed nucleus of the stria terminalis, lateral septal nucleus and the deep layers of the frontal and piriform cortices. There were also fewer A10, medial A9, and A8 DA fluorescent cells after the 6-OHDA-DMI injections; this suggests retrograde degeneration of the cells of origin of the mesolimbicocortical DA system. When the DMI pretreatment was omitted, identical bilateral 6-OHDA microinjections also produced severe loss of norepinephrine (NE) fibers in the neocortex, hippocampus, lateral hypothalamus and ventral bed nucleus of the stria terminalis. The addition of this noradrenergic damage did not change the exploratory deficits observed after mesolimbicocortical DA denervation alone. Systemic administration of the DA agonist apomorphine, but not the adrenergic agonist clonidine, to the 6-OHDA-DMI rats repaired the deficits in exploration of a novel open field or novel object. The increased locomotion in a novel open field and investigation of a novel object produced by apomorphine in 6-OHDA-DMI rats were blocked by the DA antagonist, pimozide. This is evidence that apomorphine restored exploratory responses by stimulating dopaminergic receptors. The exploratory responses produced by apomorphine were also blocked by testing rats in a familiar open field or with a familiar novel object. This is evidence that apomorphine facilitates exploratory responding to novel stimuli by 6-OHDA-DMI rats, but that the same dose of apomorphine does not increase activity when 6-OHDA-DMI rats are confronted by familiar stimuli. We conclude: (1) that mesolimbicocortical dopaminergic terminals are necessary for normal exploratory behavior in rats; and (2) that DA released by these terminals may facilitate optimal sensorimotor integration in these terminal fields during spontaneous exploratory behavior.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7417789     DOI: 10.1016/0006-8993(80)90695-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

Review 1.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

2.  Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Neha Srivastava; Rakesh Shukla; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

3.  Genetically determined predisposition to convulsions as the result of a generalized defect in the metabolism of catecholamines in the central nervous system.

Authors:  S A Dolina
Journal:  Neurosci Behav Physiol       Date:  1985 Nov-Dec

4.  Repeated imipramine enhances sensitivity of the brain dopaminergic system related to exploratory behavior.

Authors:  A Smiałowski
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

5.  Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.

Authors:  Julia C Lemos; Danielle M Friend; Alanna R Kaplan; Jung Hoon Shin; Marcelo Rubinstein; Alexxai V Kravitz; Veronica A Alvarez
Journal:  Neuron       Date:  2016-05-18       Impact factor: 17.173

6.  Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Zhihui Yang; Marcelo Febo; Zhiying Shan; Kevin K W Wang; Adriaan W Bruijnzeel
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-22       Impact factor: 4.600

7.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

8.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Rapamycin extends murine lifespan but has limited effects on aging.

Authors:  Frauke Neff; Diana Flores-Dominguez; Devon P Ryan; Marion Horsch; Susanne Schröder; Thure Adler; Luciana Caminha Afonso; Juan Antonio Aguilar-Pimentel; Lore Becker; Lillian Garrett; Wolfgang Hans; Moritz M Hettich; Richard Holtmeier; Sabine M Hölter; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildikó Rácz; Birgit Rathkolb; Jan Rozman; Beatrix Naton; Rainer Ordemann; Jerzy Adamski; Johannes Beckers; Raffi Bekeredjian; Dirk H Busch; Gerhard Ehninger; Jochen Graw; Heinz Höfler; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Jörg Stypmann; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Helmut Fuchs; Valérie Gailus-Durner; Martin Hrabe de Angelis; Dan Ehninger
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

10.  Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors.

Authors:  L Churchill; B P Roques; P W Kalivas
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.